Aptose Biosciences (TSE:APS) Sets New 52-Week Low – Here’s Why

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO)’s share price reached a new 52-week low during trading on Monday . The stock traded as low as C$4.36 and last traded at C$4.27, with a volume of 1001 shares changing hands. The stock had previously closed at C$4.36.

Wall Street Analysts Forecast Growth

Separately, Alliance Global Partners raised Aptose Biosciences to a “strong-buy” rating in a report on Thursday.

Aptose Biosciences Stock Down 5.5 %

The firm has a market capitalization of C$177.40 million, a P/E ratio of -0.82 and a beta of 1.36. The company has a debt-to-equity ratio of -117.37, a quick ratio of 5.41 and a current ratio of 1.05. The stock has a 50 day moving average of C$8.67 and a 200-day moving average of C$12.27.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.